Renee Lynn Shirley

Virogenomics, Inc.

$1,922,728

Attributed

$5,269,940

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.3M · FY2010–25

$5M$3.8M$2.5M$1.3M$0

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$5,269,940 · 4

By mechanism

UG3$3,287,052 · 1

R44$996,486 · 1

R43$581,068 · 1

R41$405,334 · 1

Top collaborators

Most similar at Virogenomics, Inc.

Same institution · by research overlap

Dennis Edward Buetow$193,689

Others in their field

Top investigators on “Safety”

David Heimbrook · Leidos Biomedical Research, Inc.$398,099,186
Lawrence Corey · Fred Hutchinson Cancer Center$396,952,463
Mitchell J Malone · Texas A&M Research Foundation$329,191,208
Gary D Acton · University Of California-Davis$320,373,312
Melynda Holmes · Technical Resources Inc$232,659,786
Beth Baseler · Leidos Biomedical Research, Inc.$225,257,316

Research focus

SafetyAnimalsDoseLeadBindingPhase I Clinical TrialsPre-ClinicalFda ApprovedInnovationInflammatoryDisease RemissionAntibodiesMigration Inhibitory FactorPharmaceutical PreparationsAttenuatedAffectBiologicalDesignBaseDrug KineticsFormulationGenerationsClinical TrialsLarge Scale Production

Grant awards (5)

IND-enabling studies and phase I clinical trials to advance CD74-target, DRhQ, as a treatment for stimulant use disorder$3,287,052

UG3 · FY2025 · DA · contact PI

Immunotherapeutic Targeting CD74 as a Treatment for Stimulant Use Disorder$405,334

R41 · FY2024 · DA · contact PI

Development of DRÎ±1-MOG-35-55 for treatment of DR2 negative MS subjects$996,486

R44 · FY2022 · AI · contact PI

Development of a plant-grown subunit vaccine against respiratory syncytial virus$290,747

R43 · FY2011 · AI · contact PI

Development of a plant-grown subunit vaccine against respiratory syncytial virus$290,321

R43 · FY2010 · AI · contact PI